Since olaparib, a potent PARP-1, PARP-2 and PARP-3 inhibitor, has shown remarkable efficacy in BRCA mutated breast cancer 65, 66, a phase I/II trial tested the combination of 300 mg of olaparib twice daily and eribulin (at standard dose and schedule) in TN advanced BC patients. This evidence concerns the gene PARP3 and breast cancer.